Trials / Unknown
UnknownNCT02526511
Perfusion Magnetic Resonance Imaging in Diagnosing Patients With Kidney Tumors
Pilot Study of Renal Neoplasms With Perfusion Magnetic Resonance Imaging
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 75 (actual)
- Sponsor
- Rutgers, The State University of New Jersey · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This pilot clinical trial studies perfusion magnetic resonance imaging in diagnosing patients with kidney tumors. Diagnostic procedures, such as perfusion magnetic resonance imaging, may help find and diagnose kidney tumors and predict and monitor a patient's response to treatment.
Detailed description
PRIMARY OBJECTIVES: I. To investigate the utility of perfusion magnetic resonance imaging (pMRI) as a diagnostic biomarker for the prediction of malignant vs. benign organ confined renal masses. II. To investigate the utility of pMRI as a therapeutic biomarker for monitoring tumor progression in patients undergoing treatment (ablation, surgery, specific systemic treatments such as interleukin 2 (IL-2) or vascular endothelial growth factor \[VEGF\]/vascular endothelial growth factor receptor \[VEGFR\]/mechanistic target of rapamycin \[mTOR\] targeted therapies) or active surveillance for organ confined or metastatic renal tumors. SECONDARY OBJECTIVES: I. To investigate the utility of pMRI to predict tumor grade and histologic subtype of organ confined kidney cancers. OUTLINE: Patients undergo dynamic contrast enhanced (DCE), dynamic susceptibility contrast (DSC), or arterial spin labeled (ASL) pMRI within 30 days of biopsy or surgery. Patients with organ confined tumors selected for active surveillance or surgery and patients with metastatic renal cell carcinoma undergo follow up pMRI at 1-6 months. After completion of study, patients are followed up within 48 hours.
Conditions
- Stage I Renal Cell Cancer
- Stage II Renal Cell Cancer
- Stage III Renal Cell Cancer
- Stage IV Renal Cell Cancer
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Arterial Spin Labeling Magnetic Resonance Imaging | Undergo arterial spin labeled perfusion magnetic resonance imaging |
| PROCEDURE | Dynamic Contrast-Enhanced Magnetic Resonance Imaging | Undergo dynamic contrast-enhanced perfusion magnetic resonance imaging |
| PROCEDURE | Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging | Undergo dynamic susceptibility contrast-enhanced perfusion magnetic resonance imaging |
| PROCEDURE | Perfusion Magnetic Resonance Imaging | Undergo perfusion magnetic resonance imaging |
Timeline
- Start date
- 2015-04-15
- Primary completion
- 2025-07-28
- Completion
- 2025-09-07
- First posted
- 2015-08-18
- Last updated
- 2023-04-11
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02526511. Inclusion in this directory is not an endorsement.